Proteins in the Bcl-2 family are central regulators of programmed cell death 1 , and members
that inhibit apoptosis, such as Bcl-X L and Bcl-2, are overexpressed in many cancers and …

The "BH3-only" proteins of the BCL-2 family require "multidomain" proapoptotic members
BAX and BAK to release cytochrome c from mitochondria and kill cells. We find short peptides …

Programmed cell death, or apoptosis, is important for the development and homeostasis of
tissues. Too little cell death can result in autoimmune diseases or cancer, whereas excessive …

There is a lack of effective predictive biomarkers to precisely assign optimal therapy to cancer
patients. While most efforts are directed at inferring drug response phenotype based on …

A powerful way to discover key genes with causal roles in oncogenesis is to identify
genomic regions that undergo frequent alteration in human cancers. Here we present high-…

Precision medicine is about matching the right drugs to the right patients. Although this
approach is technology agnostic, in cancer there is a tendency to make precision medicine …

Older patients with acute myeloid leukemia (AML) respond poorly to standard induction
therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and …

We show that the antiapoptotic proteins BCL-2, BCL-XL, MCL-1, BFL-1, and BCL-w each bear
a unique pattern of interaction with a panel of peptides derived from BH3 domains of BH3-…

We present a phase II, single-arm study evaluating 800 mg daily venetoclax, a highly selective,
oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor in patients with high-…

Background Older patients with acute myeloid leukemia (AML) have a dismal prognosis,
even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had …